Tadalafil Tablet
Product Images NDC 13668-565

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 13668-565). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Torrent Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (30ee4705 36a5 4a56 852d 9d76c40668db 01)

Chemical structure of Tadalafil, the active ingredient shown in the image, represented with its molecular bonds and rings.*

FDA Label Image

Figure 1 (30ee4705 36a5 4a56 852d 9d76c40668db 02)

Four line graphs depicting the difference in blood pressure (mmHg) between tadalafil and placebo over time (hours). The graphs show changes in standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP, with time on the x-axis and pressure difference on the y-axis, including error bars for variability.*

FDA Label Image

Figure 2 (30ee4705 36a5 4a56 852d 9d76c40668db 03)

Two line graphs showing the effect of tadalafil 20 mg combined with doxazosin 8 mg versus placebo with doxazosin 8 mg on systolic blood pressure over 24 hours post-dose. The top graph represents standing systolic blood pressure changes, and the bottom graph represents supine systolic blood pressure changes, both measured in mmHg over time in hours.*

FDA Label Image

Figure 3 (30ee4705 36a5 4a56 852d 9d76c40668db 04)

A line graph depicting systolic blood pressure (mmHg) over 12 hours after administration of 20 mg tadalafil or placebo, each combined with 8 mg doxazosin. The graph includes four data series showing blood pressure changes at 08:00 and 20:00 dosing times for both tadalafil and placebo groups, illustrating fluctuations in systolic BP after treatment.*

FDA Label Image

Figure 4 (30ee4705 36a5 4a56 852d 9d76c40668db 05)

A line graph showing plasma tadalafil concentration (µg/L) versus time (hours) for different tadalafil dosing regimens. The graph compares a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg dosing following 5 days of consecutive administration, with concentration levels plotted over a 120-hour period.*

FDA Label Image

Figure 5 (30ee4705 36a5 4a56 852d 9d76c40668db 06)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment between Tadalafil 5 mg and placebo. The x-axis represents duration of treatment in weeks (0, 4, 8, 12) and the y-axis shows change from baseline in IPSS total score, with lower values indicating greater improvement. Tadalafil 5 mg shows a greater reduction in score compared to placebo, with a statistically significant difference at week 12 (p<0.01).*

FDA Label Image

Figure 6 (30ee4705 36a5 4a56 852d 9d76c40668db 07)

A line graph depicting the change from baseline in IPSS total score over a 12-week treatment period. The x-axis represents duration of treatment in weeks (0, 1, 4, 8, 12), and the y-axis shows change in score. Two lines compare Tadalafil 5 mg and Placebo, with Tadalafil showing a greater reduction over time. Statistically significant differences (p<0.01) are marked at weeks 4 and 12.*

FDA Label Image

Figure 7 (30ee4705 36a5 4a56 852d 9d76c40668db 08)

A line graph titled 'Weeks of Therapy' showing least-squares mean change from baseline on the y-axis over 0, 4, 12, and 26 weeks on the x-axis. Two treatment groups are compared: Tadalafil/Finasteride (solid diamond line) and Placebo/Finasteride (dashed circle line). The graph includes markers for statistical significance (p<0.001 and p<0.05) and indicates least-squares treatment differences at specific time points.*

FDA Label Image

Figure 8 (30ee4705 36a5 4a56 852d 9d76c40668db 09)

A line graph displaying change from baseline in IPSS Total Score over 12 weeks of treatment. The graph compares Tadalafil 5 mg to placebo, showing greater score reduction with Tadalafil across weeks 2, 4, 8, and 12. Data points indicate statistically significant difference at 12 weeks (p<0.01). The x-axis represents weeks of treatment, and the y-axis shows change in IPSS Total Score.*

FDA Label Image

Torrent Logo (30ee4705 36a5 4a56 852d 9d76c40668db 10)

FDA Label Image

Torrent Logo-pi (30ee4705 36a5 4a56 852d 9d76c40668db 11)

FDA Label Image

Container Label 2.5 mg (30ee4705 36a5 4a56 852d 9d76c40668db 12)

Tadalafil Tablets USP 2.5 mg film-coated tablets packaging label from Torrent Pharmaceuticals Limited. The label indicates a quantity of 30 tablets with storage instructions at 25°C (77°F) and dosing guidance specifying the tablets should not be split and are for once daily use. It includes a barcode and mentions the product is Rx only.*

FDA Label Image

Container Label 5 mg (30ee4705 36a5 4a56 852d 9d76c40668db 13)

Packaging label for Tadalafil Tablets USP 5 mg by Torrent Pharmaceuticals Limited. The label indicates 30 tablets per container with storage instructions, prescription-only status, and a caution that tablets should not be split. The NDC is 13668-566-30, and the label includes directions for proper handling and dispensing.*

FDA Label Image

Container Label 10 mg (30ee4705 36a5 4a56 852d 9d76c40668db 14)

Label for Tadalafil Tablets USP 10 mg by Torrent Pharmaceuticals Limited. The label states the package contains 30 tablets, with instructions for storage between 15°C and 30°C. It includes warnings not to split tablets and to take the entire dose. The label also notes prescription-only status, manufacturer information, and a NDC number 13668-567-30.*

FDA Label Image

Container Label 20 mg (30ee4705 36a5 4a56 852d 9d76c40668db 15)

The packaging label for Tadalafil Tablets USP 20 mg shows a strip of 30 tablets. The label includes storage instructions, a warning to keep out of reach of children, and advises dispensing in a child-resistant container. It also states that tablets should not be split and the entire dose should be taken. The labeler is Torrent Pharmaceuticals Limited, with manufacturing details provided. The NDC number is 13668-568-30.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.